Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 17/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.62 |
| ▸ | PTGES | O14684 | 2/20 | 0.60 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559430 | 0.86 | TAS2R14 (0.56) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL1278616 | 0.84 | TAS2R14 (1.00) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL1278788 | 0.83 | TAS2R14 (0.97) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL1615782 | 0.82 | TAS2R14 (0.83) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL3567565 | 0.81 | CNR2 (0.60) | TAS2R14MEN1KMT2A | |
| SCHEMBL12863699 | 0.79 | TAS2R14 (0.74) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL1279120 | 0.78 | TAS2R14 (1.00) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL1279324 | 0.77 | TAS2R14 (1.00) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL1279183 | 0.77 | TAS2R14 (1.00) | TAS2R14MEN1KMT2ACXCR3PTGES | |
| SCHEMBL11814174 | 0.77 | TAS2R14 (0.61) | TAS2R14MEN1KMT2ACXCR3PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| EP-1809603-A4 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2009-09-02 | — | — | EP | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| EP-1809603-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006043839-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | TAS2R14 3281/4885MEN1 3844/4885KMT2A 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.